CyGenica

CyGenica Develops World's First Molecular Nanomachine for In Vitro and In Vivo Delivery Solutions in Drugs and Gene TherapyCyGenica has developed the world’s first molecular nanomachine for in vitro and in vivo delivery solutions in drugs and gene therapies, utilizing a proprietary and unique intracellular delivery platform to help pharmaceutical companies address unwanted “off-target” side effects, toxicity, and immunogenicity. CyGenica’s disruptive technology resolves the challenge of delivering macromolecular therapies into living cells without damaging them or triggering adverse immune responses. CyGenica is advancing groundbreaking drug delivery technologies for genomic editing to propel cutting-edge therapies for cancer and rare diseases, improving patient health and quality of life.